The role of targeted agents in the adjuvant treatment of colon cancer: a meta-analysis of randomized phase III studies and review
Metrics: PDF 1304 views | HTML 1560 views | ?
Bum Jun Kim1,*, Jae Ho Jeong2,*, Jung Han Kim1, Hyeong Su Kim1, Hyun Joo Jang3
1Department of Internal Medicine, Division of Hemato-Oncology, Kangnam Sacred Heart Hospital, Hallym University Medical Center, Hallym University College of Medicine, Seoul, Republic of Korea
2Center for Colorectal Cancer, Research Institute and Hospital, National Cancer Center, Goyang-si, Republic of Korea
3Department of Internal Medicine, Division of Gastroenterology, Dongtan Sacred Heart Hospital, Hallym University Medical Center, Hallym University College of Medicine, Hwasung, Republic of Korea
*These authors equally contributed to this work as first authors
Jung Han Kim, email: firstname.lastname@example.org
Hyeong Su Kim, email: email@example.com
Keywords: colon cancer, adjuvant treatment, targeted agent, bevacizumab, cetuximab
Received: February 13, 2017 Accepted: March 02, 2017 Published: March 10, 2017
There has been debate as to whether targeted agents have beneficial effect when added to adjuvant chemotherapy for patient with colon cancer. We conducted this meta-analysis to investigate the role of targeted agents in the adjuvant treatment of colon cancer. We searched PubMed, MEDLINE, EMBASE, and the Cochrane Library databases. We included phase III trials with the data of disease-free survival (DFS) and adverse events (AEs) of adjuvant treatment with targeted agents. From 5 eligible studies, a total of 9,991 patients with resected colon cancer were included in the meta-analysis of hazard ratio (HR) for 3-year DFS and odds ratio (OR) for grade 3 or higher AEs. The addition of targeted agents showed no improvement of 3-year DFS, compared to standard adjuvant chemotherapy alone (HR = 1.04 [95% confidence interval (CI), 0.96–1.13], P = 0.31). In the subgroup analysis according to the type of targeted agents, neither bevacizumab (HR = 1.03 [95% CI, 0.88–1.21], P = 0.72) nor cetuximab (HR = 1.11 [95% CI, 0.94–1.31], P = 0.22) was associated with improvement of DFS. Moreover, targeted agents significantly increased grade 3 or higher AEs (OR = 1.73 [95% CI, 1.21–2.46], P = 0.003) and treatment-related death (OR = 2.15 [95% CI, 1.16–3.99], P = 0.02). In conclusion, this meta-analysis demonstrates that the addition of targeted agents to standard adjuvant chemotherapy results in no improvement of DFS with increased severe AEs and treatment-related death in patients with resected colon cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.